![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Diener Hans-Christoph Ringleb Peter A Savi Pierre
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.6, Iss.5, 2005-05, pp. : 755-764
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmacotherapy for the Secondary Prevention of Stroke
Drugs, Vol. 69, Iss. 6, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Secondary Prevention of Ischemic Stroke
Current Drug Targets, Vol. 5, Iss. 5, 2004-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Strategies for the primary and secondary prevention of stroke
Inpharma, Vol. 1, Iss. 1357, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Safety of Clopidogrel and Aspirin for Stroke Prevention: Implications of the CHARISMA trial
By Ruland Sean
Drug Safety, Vol. 31, Iss. 6, 2008-01 ,pp. :